Asimenia Angelidou to BCG Vaccine
This is a "connection" page, showing publications Asimenia Angelidou has written about BCG Vaccine.
Connection Strength
2.171
-
Angelidou A, Pittet LF, Faustman D, Curtis N, Levy O. BCG vaccine's off-target effects on allergic, inflammatory, and autoimmune diseases: Worth another shot? J Allergy Clin Immunol. 2022 01; 149(1):51-54.
Score: 0.694
-
Angelidou A, Diray-Arce J, Conti MG, Netea MG, Blok BA, Liu M, Sanchez-Schmitz G, Ozonoff A, van Haren SD, Levy O. Human Newborn Monocytes Demonstrate Distinct BCG-Induced Primary and Trained Innate Cytokine Production and Metabolic Activation In Vitro. Front Immunol. 2021; 12:674334.
Score: 0.681
-
Angelidou A, Conti MG, Diray-Arce J, Benn CS, Shann F, Netea MG, Liu M, Potluri LP, Sanchez-Schmitz G, Husson R, Ozonoff A, Kampmann B, van Haren SD, Levy O. Licensed Bacille Calmette-Gu?rin (BCG) formulations differ markedly in bacterial viability, RNA content and innate immune activation. Vaccine. 2020 02 24; 38(9):2229-2240.
Score: 0.616
-
Diray-Arce J, Angelidou A, Jensen KJ, Conti MG, Kelly RS, Pettengill MA, Liu M, van Haren SD, McCulloch SD, Michelloti G, Idoko O, Kollmann TR, Kampmann B, Steen H, Ozonoff A, Lasky-Su J, Benn CS, Levy O. Bacille Calmette-Gu?rin vaccine reprograms human neonatal lipid metabolism in?vivo and in?vitro. Cell Rep. 2022 05 03; 39(5):110772.
Score: 0.180